Neogen’s High‑Vol Rally Masks a Six‑Flag Risk Warning

Why strong alpha may be outweighed by deep drawdowns and downside asymmetry

NEOG Neogen Corporation

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Neogen Corporation (NEOG) — Return Performance

Neogen Corporation (NEOG) delivered a mixed return profile over the past five years, marked by pronounced short‑term volatility and divergent performance relative to its healthcare sector benchmark (XLV). The stock posted an impressive 86.19% gain over the trailing twelve months, outpacing the sector’s 67.19% (+19.0% alpha), yet it suffered steep declines in longer horizons, including a -80.67% total return over five years versus the sector’s -152.48% (alpha of +71.81%). The one‑month and three‑month periods were negative (-0.78% and -4.2%), reflecting short‑term weakness despite underlying sector outperformance in those windows.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

NEOG

In the recent quarter, NEOG generated modest alpha of +1.81% over the sector, indicating resilience amid broader market softness; however, its three‑month return lagged with a -17.3% underperformance, suggesting heightened near‑term risk. The six‑month horizon turned sharply positive, delivering 27.32% versus the sector’s 19.46% (alpha +7.86%), highlighting a rebound that may signal upside potential if momentum persists.

Returns Overview

Neogen Corporation (NEOG) — Return Charts

Volatility Analysis

Neogen Corporation (NEOG) — Volatility Profile

Neogen Corporation exhibits markedly higher price variability than the broader market, with an annualized volatility of 40.87% compared to the S&P 500’s 17.78%, indicating more than double the fluctuation in its share price over a year. The stock’s downside risk profile is pronounced: a downside deviation of 31.07% and a historic maximum drawdown of -90.92% from April 2021 to April 2025 demonstrate severe loss potential and an extended recovery period that has not yet materialized. Recent short‑term volatility remains elevated, as the 60‑day vol of 47.25% and 252‑day vol of 59.64% both exceed the long‑term annualized figure, suggesting persistent market stress rather than a reversion to mean.

Volatility Metrics

NEOG

Neogen’s volatility is roughly 2.3 times that of the S&P 500, reflecting a riskier price trajectory for investors. The downside deviation of 31.07% underscores a higher likelihood of larger losses on down‑side moves, while the -90.92% max drawdown illustrates an extreme tail event with a multi‑year duration and no recovery to date. Both the 60‑day (47.25%) and 252‑day (59.64%) volatilities sit above the long‑term average of 40.87%, indicating that recent market conditions have amplified rather than mitigated the stock’s inherent risk.

Annualized volatility is more than double the S&P 500 benchmark.
Downside deviation exceeds 30%, signaling heightened loss sensitivity.
Maximum drawdown of -90.92% reflects an extreme, prolonged decline with no recovery.
Current short‑term volatilities (60d and 252d) are higher than the long‑term average.
The risk profile suggests a high beta exposure to market swings.

Positive Characteristics
Despite elevated risk, the stock’s price movements could offer substantial upside potential for risk‑tolerant investors.
High volatility may attract momentum‑driven strategies seeking larger price swings.

Volatility Analysis

Neogen Corporation (NEOG) — Volatility & Drawdown Charts

Beta & Correlation

Neogen Corporation (NEOG) — Beta Profile

Neogen Corporation exhibits a trailing beta of 0.925 versus the S&P 500, placing it squarely within the market‑like range (0.8‑1.2). This suggests that, on average, the stock moves in step with broader equity markets rather than behaving defensively or aggressively. However, its upside beta of 0.657 and downside beta of 0.909 reveal a pronounced asymmetry: gains are muted when the market rises, while losses track more closely to market declines, an important nuance for risk‑averse investors. The stock’s correlation with the S&P 500 stands at 0.403 and its R‑squared is only 16.2%, indicating that roughly one‑sixth of Neogen’s return variability can be explained by overall market movements. Consequently, 83.8% of its risk is idiosyncratic, meaning diversification across other assets could substantially reduce portfolio volatility. When benchmarked against the healthcare sector (XLV), the sector beta of 0.962 and sector correlation of 0.395 are marginally higher than the market figures, implying that most of Neogen’s systematic exposure stems from general equity trends rather than sector‑specific drivers.

Beta & Correlation Metrics

NEOG

Neogen’s trailing beta of 0.925 signals a stock that mirrors overall market swings without the heightened volatility of aggressive equities. The lower upside beta (0.657) suggests limited participation in rally environments, while the higher downside beta (0.909) indicates greater sensitivity during market drawdowns—a risk profile that may penalize the stock in bearish phases. With an R‑squared of 16.2% and a modest correlation of 0.403 to the S&P 500, the majority of its return variance is driven by company‑specific factors, offering potential diversification benefits. The sector beta of 0.962 versus XLV confirms that Neogen’s systematic risk is only slightly more aligned with healthcare dynamics than with the broader market, reinforcing the view that idiosyncratic risk dominates.

Trailing beta of 0.925 places Neogen in a market‑like risk bracket.
Downside beta (0.909) exceeds upside beta (0.657), indicating asymmetric downside sensitivity.
R‑squared of 16.2% means only a small portion of returns is explained by market movements.
Idiosyncratic risk accounts for 83.8% of total variance, highlighting diversification potential.
Sector beta (0.962) is marginally higher than market beta, suggesting limited sector‑specific exposure.

Positive Characteristics
Low upside beta may protect the stock during strong bull markets where sector peers outperform.
High idiosyncratic component offers investors a source of return that is less correlated with overall market risk.
Sector correlation (0.395) is slightly lower than market correlation, indicating some defensive buffering from healthcare‑specific trends.

Beta & Correlation

Neogen Corporation (NEOG) — Rolling Beta

Positive Notes

Low upside beta may protect the stock during strong bull markets where sector peers outperform.

High idiosyncratic component offers investors a source of return that is less correlated with overall market risk.

Sector correlation (0.395) is slightly lower than market correlation, indicating some defensive buffering from healthcare‑specific trends.

Risk-Adjusted Returns

Neogen Corporation (NEOG) — Risk-Adjusted Performance

Neogen Corporation (NEOG) exhibits markedly negative risk‑adjusted performance across the standard metrics, indicating that its total return has lagged the risk‑free rate after accounting for volatility and systematic risk. The Sharpe ratio of -0.038 and Treynor ratio of -1.697 both signal underperformance relative to a 3.63% risk‑free benchmark, while the negative Sortino (-0.051) confirms that downside volatility further erodes returns. Although the Calmar ratio of 0.023 suggests modest return relative to its maximum drawdown, the figure is low enough to imply that losses have been severe compared with the limited upside achieved, and an Information Ratio of -0.287 points to a lack of consistent alpha generation.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

NEOG

The Sharpe ratio (-0.038) being slightly less negative than the Sortino ratio (-0.051) indicates that total volatility is marginally lower than downside‑only volatility, yet both are below zero, confirming that risk‑adjusted returns are insufficient to compensate investors for either overall or downside risk. The Calmar ratio of 0.023 reflects a return that is only about 2.3% of the worst historical drawdown, highlighting that the stock’s price declines have been pronounced relative to its modest gains. With an Information Ratio of -0.287, the company has not delivered consistent excess returns over a benchmark, suggesting limited value from active management or strategic initiatives in the observed period.

All risk‑adjusted ratios are negative, indicating underperformance versus the risk‑free rate.
Downside risk (Sortino) is slightly worse than overall volatility (Sharpe), underscoring heightened sensitivity to losses.
The Calmar ratio of 0.023 reveals that returns are a small fraction of the maximum drawdown, pointing to severe price declines.
A negative Information Ratio (-0.287) shows a lack of consistent alpha generation.

Positive Characteristics
None identified; all metrics suggest adverse risk‑adjusted outcomes.

Risk-Adjusted Returns

Neogen Corporation (NEOG) — Rolling Sharpe & Sortino

Positive Notes

None identified; all metrics suggest adverse risk‑adjusted outcomes.

Market Regime Analysis

Neogen Corporation (NEOG) — Regime Behavior

Neogen Corporation demonstrates a pronounced sensitivity to market volatility and directionality. In bullish environments the stock delivers solid returns, though its performance moderates when volatility spikes, yielding an average monthly gain of 2.42% in Bull-HighVol versus 3.11% in Bull-LowVol. During bear markets the equity suffers steep declines, especially in orderly downtrends where it loses an average of 8.85% per month, while the loss eases slightly to 6.88% when volatility is high. The upside capture of 123.5% indicates that the company outperforms the S&P 500 during market rallies, but a downside capture of 205.2% reveals it underperforms dramatically in downturns, resulting in a net capture ratio of 0.60.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

NEOG

In the current Bull-HighVol regime, Neogen’s average monthly return of 2.42% suggests it can still generate positive momentum despite heightened market turbulence, albeit at a slower pace than in calmer bull markets. The high downside capture ratio (205.2%) signals that any shift to a bear environment would likely exacerbate losses, making the stock less defensive and more cyclical. Investors should therefore weigh the trade‑off between modest upside participation and pronounced vulnerability to market declines.

Market Regime Analysis

Neogen Corporation (NEOG) — Regime & Capture Charts

Regime Timeline

Neogen outperforms the S&P 500 in up markets with an upside capture of 123.5%, but it loses over twice as much in down markets, reflected by a downside capture of 205.2%.
The stock’s performance deteriorates when market volatility rises, dropping from a 3.11% average monthly gain in Bull-LowVol to 2.42% in Bull-HighVol.
Bear regimes are particularly painful, with an 8.85% average monthly loss in Bear‑LowVol and a still severe 6.88% loss when volatility is high.
The overall capture ratio of 0.60 indicates that Neogen captures less upside than downside relative to the broader market, highlighting asymmetric risk.

Positive Characteristics
Strong upside participation during bullish periods (upside capture >120%).
Ability to generate positive returns even in a volatile bull environment.

Investment Highlights & Risk Summary

Neogen Corporation (NEOG) — Summary & Implications

Neogen Corporation delivered an exceptional 1‑year total return of 86.19%, generating an alpha of 67.19% versus the S&P 500 and outpacing its healthcare sector benchmark (XLV) by 71.66%. The stock’s upside capture of 123.5% indicates it participated strongly in market rallies, while a beta of 0.925 suggests overall price movements track the broader market with slightly lower sensitivity. However, risk metrics are markedly adverse: a Sharpe ratio of –0.038 and Sortino of –0.051 signal that returns have not compensated for risk, volatility is elevated at 40.87% annualized, and the historic maximum drawdown of –90.92% underscores severe downside potential. Investors must weigh the impressive absolute performance against pronounced asymmetries—downside capture of 205.2% and a higher downside beta (0.91) than upside beta (0.66)—which could amplify losses in market downturns.

Summary Dashboard

Investment Highlights

1‑year total return of 86.19% represents a substantial absolute gain, far exceeding the S&P 500’s approximate 19% annual performance.
Alpha of 67.19% versus the S&P 500 and sector alpha of 71.66% demonstrate that Neogen has delivered superior risk‑adjusted excess returns relative to both the broad market and its healthcare peers.
Upside capture of 123.5% shows the stock participates more than proportionally in bullish market phases, providing upside potential when equities rally.
Overall beta of 0.925 indicates exposure slightly below market volatility, which can be attractive for investors seeking equity-like returns with modest systematic risk.

Risk-Return Rankings

NEOG HIGH

High‑return stock with strong outperformance but extreme downside risk and negative risk‑adjusted metrics.

Strength: Exceptional 1‑year return and alpha versus both market and sector benchmarks.

Concern: Maximum drawdown of –90.92% and negative Sharpe ratio reflect severe capital loss risk.

Key Takeaways

Neogen’s outsize return and alpha make it a standout performer in the healthcare space over the past year.
Negative Sharpe and Sortino ratios indicate that the high returns have come with disproportionate risk, failing to exceed the risk‑free rate on a risk‑adjusted basis.
The stock’s downside capture of 205.2% and higher downside beta suggest it magnifies market declines, posing a significant tail‑risk exposure.
Elevated volatility (40.87%) combined with a historic near‑total drawdown underscores the potential for rapid equity erosion during adverse periods.

PORTFOLIO IMPLICATIONS

Neogen may serve as a high‑conviction satellite position for investors seeking aggressive upside exposure within healthcare, particularly if paired with core holdings that have low beta and defensive characteristics to offset its downside asymmetry. Given its pronounced volatility and deep drawdown history, allocating a modest percentage of the portfolio—preferably in a diversified, risk‑managed framework—can help capture upside potential while limiting overall portfolio drawdowns. Investors should monitor market conditions closely; the stock’s performance is likely to diverge sharply from broader equity trends during periods of heightened market stress.

NEOG

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.